 | | Recently Published Opportunities | Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional)
Notice Number
RFA-OD-20-013
Key Dates
Open Date (Earliest Submission Date): July 8, 2020
Application Due Date: August 7, 2020
Expiration Date: August 8, 2020
Purpose
NIH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency cooperative agreement funding opportunity announcement (FOA) from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) initiative, a consortium of community-engaged research projects to understand factors that have led to disproportionate burden of the pandemic on the underserved and/or vulnerable populations so that interventions can be implemented to decrease these disparities. This FOA seeks to fund a single Coordination and Data Collection Center (CDCC) as an integral part of the consortium. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.
View RFA-OD-20-013
Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations
Notice Number
NOT-OD-20-119
Key Dates
Release Date: June 12, 2020
First Available Due Date: July 8, 2020
Expiration Date: September 9, 2020
Purpose
This Notice of Special Interest (NOSI) highlights the urgent need to understand the social, ethical, and behavioral implications (SEBI) of COVID-19 testing among underserved and/or vulnerable populations across the United States through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. The funding for this supplement is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.
View NOT-OD-20-119
Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations
Notice Number
NOT-OD-20-120
Key Dates
Release Date: June 12, 2020
First Available Due Date: July 8, 2020
Expiration Date: September 9, 2020
Purpose
This Notice of Special Interest (NOSI) highlights the urgent need to understand and address COVID-19 morbidity and mortality disparities among underserved and vulnerable populations across the United States. These two-year community-engaged Testing Research Projects will examine SARS-CoV-2 infection patterns and efforts to increase access and effectiveness of diagnostic methods through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. The funding for this supplement program is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.
View NOT-OD-20-120
Notice of Special Interest (NOSI): Limited Competition for Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations
Notice Number
NOT-OD-20-121
Key Dates
Release Date: June 12, 2020
First Available Due Date: August 7, 2020
Expiration Date: August 8, 2020
Purpose
This Notice of Special Interest (NOSI) highlights the urgent need to understand and address COVID-19 morbidity and mortality disparities among underserved and vulnerable populations across the United States. These two-year community-engaged Testing Research Projects will examine SARS-CoV-2 infection patterns and efforts to increase access and effectiveness of diagnostic methods through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. The funding for this supplement program is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.
View NOT-OD-20-121
Mid-Career Enhancement Awards to Integrate Basic Behavioral, Biomedical, and/or Social Scientific Processes
(K18 Basic Experimental Studies with Humans Required)
Notice Number
PAR-20-226
Key Dates
Open Date (Earliest Submission Date): February 16, 2021
Application Due Date(s): March 17, 2021, March 17, 2022, March 17, 2023
Expiration Date: March 18, 2023
Purpose
This Funding Opportunity Announcement (FOA) invites applications from investigators who strive to expand their research trajectories through the acquisition of new knowledge and skills in the areas of basic psychological processes, sociological processes, and/or biomedical pathways—expertise that is beyond and enhances their current areas of expertise. The program will support career development experiences and a small-scale research project that will provide experienced investigators with the scientific competencies required to conduct independent research projects that more thoroughly investigate interrelationships among behavioral, biological, endocrine, epigenetic, immune, inflammatory, neurological, psychological, and/or social processes. Eligible candidates are independent investigators at mid-career faculty rank or level.
View PAR-20-226
Mid-Career Enhancement Awards to Integrate Basic Behavioral, Biomedical, and/or Social Scientific Processes
(K18 No Independent Clinical Trials)
Notice Number
PAR-20-211
Key Dates
Open Date (Earliest Submission Date): February 16, 2021
Application Due Date(s): March 17, 2021, March 17, 2022, March 17, 2023
Expiration Date: March 18, 2023
Purpose
This Funding Opportunity Announcement (FOA) invites applications from investigators who strive to expand their research trajectories through the acquisition of new knowledge and skills in the areas of basic psychological processes, sociological processes, and/or biomedical pathways—expertise that is beyond and enhances their current areas of expertise. The program will support career development experiences and a small-scale research project that will provide experienced investigators with the scientific competencies required to conduct independent research projects that more thoroughly investigate interrelationships among behavioral, biological, endocrine, epigenetic, immune, inflammatory, neurological, psychological, and/or social processes. Applicants may propose research that involves non-human animals, secondary data analyses, or other career development projects that do not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants are permitted to propose research experience within a clinical trial led by a mentor or co-mentor. Eligible candidates are independent investigators at mid-career faculty rank or level.
This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study,or an ancillary study to a clinical trial.Applicants proposing Basic Experimental Studies with Humans (BESH) should apply to the companion FOA PAR-20-226.
View PAR 20-211
NIH Director's Pioneer Award Program
(DP1 Clinical Trial Optional)
Notice Number
RFA-RM-20-011
Key Dates
Open Date (Earliest Submission Date): August 11, 2020
Application Due Date: September 11, 2020
Expiration Date: September 12, 2020
Purpose
The NIH Director's Pioneer Award Program supports individual scientists of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation's research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator's research program or elsewhere. The NIH Director's Pioneer Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund.
View RFA-RM-20-011
NIH Director's New Innovator Award Program
(DP2 Clinical Trial Optional)
Notice Number
RFA-RM-20-012
Key Dates
Open Date (Earliest Submission Date): July 21, 2020
Application Due Date: August 21, 2020
Expiration Date: August 22, 2020
Purpose
The NIH Director's New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director's New Innovator Award Program complements other ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators. The NIH Director's New Innovator Award Program is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund.
View RFA-RM-20-012
NIH Director's Transformative Research Awards
(R01 Clinical Trial Optional)
Notice Number
RFA-RM-20-013
Key Dates
Open Date (Earliest Submission Date): August 31, 2020
Application Due Date: September 30, 2020
Expiration Date: October 1, 2020
Purpose
The NIH Director's Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation's research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications are welcome in all topics relevant to the broad mission of NIH, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in a broad area of relevance to the NIH. The NIH Director's Transformative Research Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund. Those wishing to apply for the NIH Director's Emergency Transformative Research Award for SARS-CoV-2-related research must apply in response to RFA-RM-20-020.
View RFA-RM-20-013
NIH Director's Early Independence Awards
(DP5 Clinical Trial Optional)
Notice Number
RFA-RM-20-014
Key Dates
Open Date (Earliest Submission Date): August 4, 2020
Application Due Date: September 4, 2020
Expiration Date: September 5, 2020
Purpose
The NIH Director's Early Independence Award supports exceptional junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director's Early Independence Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund. Those wishing to apply for the NIH Director's Emergency Early Independence Award for SARS-CoV-2-related research must apply in response to RFA-RM-20-021.
View RFA-RM-20-014
NIH Director's Emergency Transformative Research Awards
(R01 Clinical Trial Optional)
Notice Number
RFA-RM-20-020
Key Dates
Open Date (Earliest Submission Date): August 30, 2020
Application Due Date: September 30, 2020
Expiration Date: October 1, 2020
Purpose
This FOA solicits applications responsive only to the COVID-19 public health emergency through support of the CARES Act. All other Transformative Research Award applications must be submitted in response to RFA-RM-20-013.
The NIH Director's Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation's research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact on SARS-CoV-2 prevention, preparation, or response. The NIH Director's Transformative Research Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund.
Due to the COVID-19 public health emergency, the Common Fund will dedicate funds provided by the CARES Act to support a total of 5-10 Transformative Research Awards (through this FOA) or Early Independence Awards (through RFA-RM-20-021) that bring new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally. Any relevant area of coronavirus SARS-CoV-2 research is welcome, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics. As with all High-Risk, High-Reward Research program applications, innovation may be technological or conceptual.
View RFA-RM-20-020
NIH Director's Emergency Early Independence Awards
(DP5 Clinical Trial Optional)
Notice Number
RFA-RM-20-021
Key Dates
Open Date (Earliest Submission Date): August 4, 2020
Application Due Date: September 4, 2020
Expiration Date: September 5, 2020
Purpose
This FOA solicits applications responsive only to the COVID-19 public health emergency through support of the CARES Act. All other Early Independence Award applications must be submitted in response to RFA-RM-20-014.
The NIH Director's Early Independence Award (a component of the High-Risk, High-Reward Research program of the NIH Common Fund) supports exceptional junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement.
Due to the COVID-19 public health emergency, the Common Fund will dedicate funds provided by the CARES Act to support a total of 5-10 Early Independence Awards (through this FOA) or Transformative Research Awards (through RFA-RM-20-020) that bring new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally. Any relevant area of coronavirus SARS-CoV-2 research is welcome, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics. As with all High-Risk, High-Reward Research program applications, innovation may be technological or conceptual.
View RFA-RM-20-021
|
No comments:
Post a Comment